Renovaro
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 12
- Market Cap
- $106.1M
- Introduction
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Renovaro Issues Shareholder Letter and Provides Corporate Update
Renovaro Inc. updates shareholders on progress, focusing on AI-powered cancer diagnostics and therapeutics. Key initiatives include acquiring Predictive Oncology for its extensive tumor database, enhancing AI/ML for cancer detection and vaccine development, and strategic collaborations. The company plans an international roadshow starting January 13, 2025, to engage investors.
Stock Market News Today: SoundHound AI's Voice Commerce, Accenture's AI Report, OraSure's HIV Testing Expansion, Paychex's Acquisition, T2 Biosystems' Growth, Hasbro's MONOPOLY Update, Verizon's 5G Enhancement, Nokia's Lunar Network, Backblaze's Canada Expansion, Illumina's NovaSeq X Series Advancement
SoundHound AI unveiled a voice commerce platform for cars at CES 2025. Accenture's report highlights AI's role in business reinvention. OraSure expanded HIV self-testing to adolescents. Paychex acquired Paycor HCM for $4.1B. T2 Biosystems saw 37% revenue growth. Hasbro updated MONOPOLY for its 90th anniversary. Verizon enhanced 5G for the U.S. Air Force. Nokia completed a lunar cellular network. Backblaze expanded in Canada. Illumina advanced its NovaSeq X Series.
Predictive Oncology Announces Agreement to be Acquired
Predictive Oncology Inc. to merge with Renovaro, Inc., leveraging AI/ML platforms to enhance cancer patient outcomes. The deal involves a stock exchange, aiming for cost savings and accelerated drug discovery. The merger is pending shareholder approval and a $15M fundraising by Renovaro.
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Renovaro Inc. announces acquisition of Predictive Oncology, combining AI-driven platforms to advance cancer diagnostics and drug discovery. The deal leverages Predictive's biobank of 150,000 tumor samples and AI/ML platform with 92% accuracy in predicting tumor-drug response, aiming to improve personalized cancer therapy outcomes.
Predictive Oncology Announces Agreement to be Acquired by Renovaro
Predictive Oncology Inc. announced a merger with Renovaro, Inc., leveraging AI/ML platforms to enhance cancer patient outcomes. The deal involves exchanging Predictive Oncology's common stock for Renovaro's preferred stock, aiming for scientific synergies and cost savings. The merger is pending shareholder approval and a $15 million fundraising by Renovaro.
Predictive Oncology to Be Acquired by Renovaro in AI Merger Aimed at Enhancing Cancer Patient Outcomes
Predictive Oncology Inc. (NASDAQ: POAI) announced a binding letter of intent to be acquired by Renovaro, Inc. (NASDAQ: RENB) in exchange for Renovaro preferred stock. The merger aims to combine AI/ML platforms to enhance cancer patient outcomes, achieve over 30% cost savings, and leverage Predictive Oncology's biobank and Renovaro's AI expertise. The deal includes specific terms for stock exchange, redemption, and conversion, pending shareholder approval and Renovaro's minimum $15 million fundraising.
© Copyright 2025. All Rights Reserved by MedPath